EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment

Sami F Qadri

Diabetologia · 2026-11 · 69 (11) · 3048-3072

DOI: 10.1007/s00125-026-06816-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetologia, online erschienen am 06.08.2026. Verfasst von Sami F Qadri. Beteiligte Einrichtung: Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. sami.qadri@helsinki.fi. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Diseases, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Helsinki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most people with type 2 diabetes have metabolic dysfunction-associated steatotic liver disease (MASLD), yet fewer than 2% experience major adverse liver outcomes within 10 years. Because progression to end-stage liver disease is uncommon, identifying the small subset of individuals at highest risk remains a central clinical challenge. Liver fibrosis is the strongest prognostic determinant in MASLD, and a range of blood-based and imaging tests are used to assess the likelihood of advanced fibrosis (AF) in the clinic. Since 2023, major medical societies have recommended systematic screening for MASLD-related AF in individuals with type 2 diabetes, driven by reports suggesting a high prevalence of up to 20–40%. This review critically examines the evidence underlying these recommendations while providing a clinically oriented guide to diagnosing MASLD in type 2 diabetes. Re-analysis of data from prevalence studies suggests that the burden of AF in type 2 diabetes has been substantially overestimated and may be below 5–10%, which has profound implications for both the rationale for screening and its expected yield. Simulations and emerging real-world evidence suggest that current non-invasive tests may refer 30–50% of patients for costly second-line testing and 15% for specialist evaluation, while generating high false-positive rates and missing more than a third of all AF cases. Moreover, it remains uncertain whether diagnosing AF in type 2 diabetes currently leads to meaningful changes in management or outcomes. Existing cost-effectiveness analyses rely on assumptions about disease burden and therapeutic benefit that are not supported by available data. Together, these considerations call for a more rigorous, evidence-based approach to evaluating liver disease risk in type 2 diabetes and other populations. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Liver DiseasesFatty LiverHumansMass ScreeningLiver CirrhosisPrevalenceEvidence-Based Medicine

Stichwörter der Autor:innen

Bayesian analysisBiomarkersCost-effectivenessDiagnosisFatty liverFibrosisMetabolic dysfunction-associated steatotic liver diseasePrevalenceReviewScreeningType 2 diabetes

Autor:innen und Institutionen

  • Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. sami.qadri@helsinki.fi.
  • Minerva Foundation Institute for Medical Research, Helsinki, Finland. sami.qadri@helsinki.fi.

Förderung

  • University of Helsinki

Zitieren

APA

Qadri, S. F. (2026). Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment. Diabetologia, 69(11), 3048-3072. https://doi.org/10.1007/s00125-026-06816-0

Vancouver

Qadri SF. Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment. Diabetologia. 2026;69(11):3048-3072. doi:10.1007/s00125-026-06816-0

BibTeX
@article{Qadri2026,
  author = {Qadri, Sami F},
  title = {Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment},
  journal = {Diabetologia},
  year = {2026},
  volume = {69},
  number = {11},
  pages = {3048--3072},
  doi = {10.1007/s00125-026-06816-0}
}
Kostenlos starten →